Regenerative medicine firm Tissue Regenix has named Steve Couldwell as its new CEO, following the departure of Anthony Odell, who led the group for over a decade. (Also see "Change At Helm As Tissue Regenix Enters Next Growth Phase" - Medtech Insight, 18 October, 2017.). Couldwell has been a non-executive director for the company since July 2013.
In October, Leeds, UK-based Tissue Regenix told Medtech Insight that Odell had stepped down with the agreement of the board of directors as the business moved into a new phase...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?